Ranbaxy Laboratories Ltd said on Monday drug regulators in the UK and Australia had approved its manufacturing facility in north India that was earlier the target of US regulatory action.
Ranbaxy, majority owned by Japan's Daiichi Sankyo, said Medicines and Healthcare products Regulatory Agency (MHRA) of the UK and Australia's Therapeutic Goods Administration issued "good manufacturing practice" certificates for the Paonta Sahib facility after a joint audit conducted last October. The drugmaker said the MHRA approval would apply to its product filings for the entire European Union. In February, the US Food and Drug Administration halted reviews of drug applications from Paonta Sahib plant saying test results submitted in approved and pending drug applications were found to have been falsified. B.KARTHICK RESEARCH ANALYST WWW.KENCES1.BLOGSPOT.COM <http://www.kences1.blogspot.com/> --~--~---------~--~----~------------~-------~--~----~ You received this message because you are subscribed to the Google Groups "Kences1" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [email protected] For more options, visit this group at http://groups.google.com/group/kences1?hl=en -~----------~----~----~----~------~----~------~--~---
